Section 2 – Department Outcomes – 2 Access to Pharmaceutical Services
Outcome 2
Access to cost-effective medicines, including through the Pharmaceutical Benefits
Scheme and related subsidies, and assistance for medication management through
industry partnerships
Outcome Strategy
The Australian Government, through Outcome 2, provides reliable, timely and
affordable access to cost-effective, sustainable and high quality medicines and
pharmaceutical services. The Government does this through subsidising the cost of
medicines through the Pharmaceutical Benefits Scheme (PBS), by providing free
access to expensive and ‘life-saving’ drugs, and by supporting the provision of aids
and appliances. The Government also provides advice and support to health
professionals and consumers on the quality use of medicines, and works with the
pharmaceutical industry to ensure the supply of medicines through the PBS.
The National Medicines Policy provides an overarching framework for the
activities in Outcome 2. There are four central objectives of the policy: timely access
to medicines at an affordable cost to individuals and the community; medicines
should meet quality, safety and efficacy standards; quality use of medicines; and
maintaining a responsible and viable medicines industry.
Under the National Medicines Policy, the Australian Government provides advice
and support to health professionals and consumers on the quality use of
medicines, along with programs aimed at improving the use of medicines in the
community, improving health outcomes for patients and increasing the
sustainability of the PBS.
Through the Fifth Community Pharmacy Agreement (the Fifth Agreement),
the Government will provide funding and support to around 5,000 pharmacies
to continue dispensing PBS medicines. The Government collaborates with
community pharmacies, peak bodies and consumers to implement the
Fifth Agreement.
Ensuring the sustainability of this system and access to innovative treatments for
Australian consumers is of the utmost importance to the Government.
The 2010 PBS reforms and Price Disclosure continue to be a highly effective
mechanism for ensuring the sustainability of the PBS and making head room for
new medicines.
For example the expanded and accelerated price disclosure reforms of 2010
continue to deliver price cuts of between 10% and 87% whilst following the market
rather than setting it.
These reforms continue to reduce the price of medicines for the consumer as well
as Government. In its first year of operation the 2010 reforms delivered $1.9 billion
of price cuts to the PBS. The price changes that have occurred or will occur in 2013
73
Outcome I 02
ACCESS TO PHARMACEUTICAL SERVICES
Budget Statements – Department of Health and Ageing
and beyond will reduce the forward estimates by a further $2 billion, around
$4 billion in savings, since these reforms commenced.
The Government will continue to implement and monitor pricing reforms and
other initiatives agreed to under the Memorandum of Understanding with
Medicines Australia, such as the Managed Entry Scheme and Parallel Processing.
Consumers and key stakeholder groups such as Medicines Australia, the Generics
Medicines Industry Association and the Consumers Health Forum, continue to be
consulted through this process.
Outcome 2 is the responsibility of Pharmaceutical Benefits Division.
Programs Contributing to Outcome 2
Program 2.1: Community pharmacy and pharmaceutical awareness
Program 2.2: Pharmaceuticals and pharmaceutical services
Program 2.3: Targeted assistance – pharmaceuticals
Program 2.4: Targeted assistance – aids and appliances
74
Section 2 – Department Outcomes – 2 Access to Pharmaceutical Services
Outcome 2 Budgeted Expenses and Resources
Table 2.1 provides an overview of the total expenses for Outcome 2 by program.
Program 2.1: Community pharmacy and pharmaceutical awareness
Administered expenses
Ordinary annual services (Appropriation Bill No. 1)
Departmental expenses
Departmental appropriation1
Expenses not requiring appropriation in the budget year2
Total for Program 2.1
Program 2.2: Pharmaceuticals and pharmaceutical services
Administered expenses
Ordinary annual services (Appropriation Bill No. 1)
Special appropriations
National Health Act 1953 - pharmaceutical benefits
Departmental expenses
Departmental appropriation1
Expenses not requiring appropriation in the budget year2
Total for Program 2.2
Program 2.3: Targeted assistance - pharmaceuticals
Administered expenses
Ordinary annual services (Appropriation Bill No. 1)
Departmental expenses
Departmental appropriation1
Expenses not requiring appropriation in the budget year2
Total for Program 2.3
Program 2.4: Targeted assistance - aids and appliances
Administered expenses
Ordinary annual services (Appropriation Bill No. 1)
Special appropriations
National Health Act 1953 - aids and appliances
Departmental expenses
Departmental appropriation1
Expenses not requiring appropriation in the budget year2
Total for Program 2.4
75
2012-13
Estimated
actual
$'000
2013-14
Estimated
expenses
$'000
333,854
367,130
6,784
157
340,795
6,274
212
373,616
190,182
193,135
9,466,358
9,878,169
36,521
1,191
9,694,252
35,730
1,482
10,108,516
151,016
153,336
3,292
76
154,384
3,045
103
156,484
745
681
284,592
304,915
3,292
76
288,705
3,045
103
308,744
Outcome I 02
Table 2.1: Budgeted Expenses and Resources for Outcome 2
Budget Statements – Department of Health and Ageing
Table 2.1: Budgeted Expenses and Resources for Outcome 2 (cont.)
2012-13
Estimated
actual1
$'000
2013-14
Estimated
expenses1
$'000
675,797
9,750,950
714,282
10,183,084
49,889
1,500
48,094
1,900
10,478,136
10,947,360
2012-13
230
2013-14
214
Outcome 2 totals by appropriation type
Administered expenses
Ordinary annual services (Appropriation Bill No. 1)
Special appropriations
Departmental expenses
Departmental appropriation1
Expenses not requiring appropriation in the budget year2
Total expenses for Outcome 2
Average staffing level (number)
1
2
Departmental appropriation combines “Ordinary annual services (Appropriation Bill No 1)” and “Revenue from
independent sources (s31)’.
“Expenses not requiring appropriation in the Budget year” is made up of depreciation expense amortisation
expense, makegood expense and audit fees.
Program 2.1: Community pharmacy and pharmaceutical
awareness
Program Objectives
Support timely access to medicines and pharmacy services through the Fifth Community
Pharmacy Agreement
The Australian Government will ensure all eligible Australians continue to have
timely access to PBS medicines and other professional services through the Fifth
Agreement. The Fifth Agreement provides funding over five years, from 2010-11 to
2014-15, to remunerate pharmacists for dispensing PBS medicines and provide a
range of professional programs and services that aim to improve consumer health
outcomes. These include services to support medication management, programs to
assist the pharmacy workforce, activities to support improved service quality, and
ongoing research and development work to inform future service delivery models.
In 2013-14, the Department will continue over 20 programs to support the delivery
of pharmaceutical services and quality use of medicines through community
pharmacies. These initiatives include the Electronic Recording and Reporting of
Controlled Drugs Supply (which aims to collect and report real time data relating
to controlled drugs to help address problems of forgery, abuse and prescription
shopping), and PBS Claiming from a Medication Chart in Residential Aged Care
Facilities (which aims to improve medication safety for residents, and decrease the
duplication of paperwork and administrative burden) and Continued Dispensing
of PBS Medicines in Defined Circumstances (which aims to maintain patient
adherence to therapy by preventing treatment interruption due to the inability to
obtain a timely prescription renewal).
The Department will support the sustainability of community pharmacies in rural
and remote Australia through a range of targeted programs. These programs will
76
Section 2 – Department Outcomes – 2 Access to Pharmaceutical Services
The Department will continue to support the Medication Management Review
(MMR) programs which aim to improve the quality use of medicines and reduce
medication misadventure among people using multiple medicines. The MMR
programs will be supported by the ongoing roll out of the MedsCheck and
Diabetes MedsCheck program which assists services that focus on improving
consumer education and management of their medicines.
The Department will continue to work with the Pharmacy Guild of Australia to
ensure all Fifth Agreement programs are sustainable within the available Fifth
Agreement allocation by re-prioritising funding between programs to ensure that
services continue to meet consumer expectations and needs and overall
expenditure is not exceeded. The effectiveness of these programs will be reviewed
in the context of the Fifth Agreement Evaluation Framework. Programs with a
medication management focus will be specifically reviewed under the Combined
Review of Fifth Agreement Medication Management Programs. The progress and
reports of all the reviews will be made available on the Department’s website.
Program 2.1 is linked as follows:

The Department of Human Services (Services to the Community –
Program 1.1) administer payments under various professional programs and
services contained within the Fifth Community Pharmacy Agreement. This
includes payments to claiming pharmacists for Medication Management
Programs, and payments to pharmacies that participate in the Pharmacy
Practice Incentive Program.
Program 2.1: Expenses
Table 2.2: Program Expenses
Annual administered expenses
Ordinary annual services
Program support
Total Program 2.1 expenses
2012-13
Estimated
actual
$'000
2013-14
Budget
333,854
6,941
340,795
77
$'000
2014-15
Forward
year 1
$'000
2015-16
Forward
year 2
$'000
2016-17
Forward
year 3
$'000
367,130
6,486
373,616
400,900
6,440
407,340
400,920
6,479
407,399
400,942
6,586
407,528
Outcome I 02
address challenges specific to rural pharmacists including continuing professional
education, locum services and undergraduate support.
Budget Statements – Department of Health and Ageing
Program 2.1: Deliverables
Qualitative Deliverables for Program 2.1
Support timely access to medicines and pharmacy services through the Fifth
Community Pharmacy Agreement
Qualitative Deliverables
2013-14 Reference Point or Target
Phased roll out of measure: Electronic
Recording and Reporting of Controlled Drugs
Continue measure phase in, for completion
during the first half of 2013-14, including
working with jurisdictions to facilitate the
delivery of this measure1
Phased roll out of measure: Supply and PBS
Claiming from a Medication Chart in
Residential Aged Care Facilities
Continue measure phase in, for completion
during 2013-14, including evaluation of the
National Residential Medication Chart in
pilot sites prior to consideration of a national
rollout
Phased roll out of measure: Continued
Dispensing of PBS Medicines in Defined
Circumstances
Continue measure phase in, for completion
during 2013-14, dependent on state and
territory enabling legislation being
introduced to facilitate the delivery of this
measure
Quantitative Deliverable for Program 2.1
Support timely access to medicines and pharmacy services through the Fifth
Community Pharmacy Agreement
Quantitative Deliverable
Number of medication
management services
provided under the Fifth
Agreement
1
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
63,000
64,500
66,000
67,500
69,000
Implementation of the system will vary across the jurisdictions as states and territories need to make necessary
legislative changes to ensure the system can migrate with existing technologies and processes.
78
Section 2 – Department Outcomes – 2 Access to Pharmaceutical Services
Program 2.1: Key Performance Indicators
Quantitative Key Performance Indicators for Program 2.1
Quantitative
Indicators
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
Percentage of rural
community pharmacies
accessing targeted rural
programs to support the
sustainability of community
pharmacy in rural and
remote Australia2
70%
75%
80%
80%
81%
Percentage of community
pharmacies participating in
the Pharmacy Practice
Incentives Program3
45%
90%
91%
91%
92%
Program 2.2: Pharmaceuticals and pharmaceutical services
Program Objectives
List cost-effective, innovative, clinically effective medicines on the PBS
The PBS is the primary means through which the Australian Government ensures
Australians have timely and affordable access to pharmaceuticals. In 2012-13, the
PBS is expected to cost $9.5 billion, increasing to $9.9 billion in 2013-14.
The listing of medicines on the PBS is based on the advice of the Pharmaceutical
Benefits Advisory Committee (PBAC), an independent, expert advisory body
comprising doctors, other health professionals and a consumer representative.
The PBAC assesses the safety, therapeutic benefits and cost-effectiveness of the
medicine for the intended use, in comparison with other available treatments.
Since the Mid Year Economic and Fiscal Outlook in October 2012, the Government
has approved a number of new or amended PBS listings, at an overall net cost of
$692 million over five years, including the listing of pregabalin (Lyrica®) for the
treatment of chronic pain on 1 March 2013, and the listing of two new innovative
medicines, boceprevir (Victrelis®) and telaprevir (Incivo®), to treat Hepatitis C.
Increase the sustainability of the PBS
The Government ensures that the PBS is managed in a fiscally responsible and
sustainable way, so that the Australian community will continue to have access to
affordable medicines into the future.
2
Targets have been revised as uptake of the program has been greater than expected.
3
Targets have been revised as uptake of the program has been greater than expected.
79
Outcome I 02
Support timely access to medicines and pharmacy services through the Fifth
Community Pharmacy Agreement
Budget Statements – Department of Health and Ageing
Further PBS reforms not only deliver savings to taxpayers but also deliver savings
direct to consumers’ pockets. For example by the end of 2013 treatments for
gastrointestinal conditions, blood pressure, depression and cholesterol are
expected to be up to almost $16 a packet cheaper for consumers compared to what
they were paying in 2011, as a result of the price cuts under the 2010 PBS reforms.
Price Disclosure is expected to achieve a further saving of $2 billion through price
reductions occurring in 2013 and beyond. These reforms use market prices to
achieve ongoing savings to the PBS providing the Government the ability to list
new and innovative medicines as they become available.
Price disclosure is one of the primary means through which the Government will
continue to reduce the costs of PBS subsidised drugs. It requires suppliers of
medicines to disclose the prices they charge to pharmacies, allowing prices paid
under the PBS to be revised to reflect the weighted average prices actually charged
in the market. Price disclosure now applies to more than 300 drugs. Further
reductions are scheduled for 1 August 2013, 1 December 2013 and 1 April 2014.
The Department will also work with the pharmaceutical industry to balance the
need to promote competition in the industry through the use of generic medicines
without discouraging investment in pharmaceutical research and innovation.
Post Market Surveillance
In 2013-14, the Government will continue to progress several reviews of medicines
in use, focusing on the appropriate and quality use of medicines to help improve
health outcomes for patients and ensure continued value for money for taxpayers.
Quality Use of Medicines
In 2013-14, the Department will continue to apply the National Medicines Policy
through collaboration with National Medicines Policy partners to improve the
quality use of medicines in the community, including considering issues such as
antimicrobial resistance and health literacy.
Increased funding for chemotherapy services
In 2013-14, the Department will undertake a comprehensive review of funding
arrangements for chemotherapy services. From 1 July 2013 to 31 December 2013,
additional funding of $60 per infusion will ensure the ongoing viability of
chemotherapy services. The review of chemotherapy arrangements will report to
the Minister for Health by October 2013 with recommendations on a longer-term
sustainable approach to funding chemotherapy services.
Program 2.2 is linked as follows:

The Department of Human Services (Services to the Community –
Program 1.1) to administer the PBS, including payment of script benefits,
authority approvals, new and other PBS items.
80
Section 2 – Department Outcomes – 2 Access to Pharmaceutical Services
Program 2.2: Expenses
Annual administered expenses
Ordinary annual services
Special appropriations
National Health Act 1953 pharmaceutical benefits
Program support
Total Program 2.2 expenses
2012-13
Estimated
actual
$'000
2013-14
Budget
$'000
2014-15
Forward
year 1
$'000
2015-16
Forward
year 2
$'000
2016-17
Forward
year 3
$'000
190,182
193,135
196,316
199,528
199,468
9,466,358
9,878,169
10,374,106
10,811,795
11,284,504
37,712
37,212
36,478
35,365
35,845
9,694,252
10,108,516
10,606,900
11,046,688
11,519,817
Program 2.2: Deliverables
Qualitative Deliverables for Program 2.2
List cost-effective, innovative, clinically effective medicines on the PBS
Qualitative Deliverables
2013-14 Reference Point or Target
The PBAC meets at least three times a year and
provides recommendations to the Minister on
new listings for the PBS
The PBAC recommendations for listing on
the PBS are based on the clinical
effectiveness and cost-effectiveness of new
medicines, and provided in a timely manner
Price negotiations with sponsors and
conditions for listing finalised, and quality and
availability checks undertaken for new PBS
listings
All negotiations and listing activity
completed in a timely manner
Post Market Surveillance
Qualitative Deliverable
2013-14 Reference Point or Target
Undertake reviews of medicines in use,
focussing on the appropriate and quality use
of medicines
Complete two reviews in 2013-14: medicines
used to treat asthma in children and
medicines and products used to manage
diabetes
81
Outcome I 02
Table 2.3: Program Expenses
Budget Statements – Department of Health and Ageing
Quantitative Deliverable for Program 2.2
List cost-effective, innovative, clinically effective medicines on the PBS
Quantitative Deliverable
Percentage of the
community’s (public)
comments included for
consideration at each
Pharmaceutical Benefits
Advisory Committee
meeting
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
100%
100%
100%
100%
100%
Program 2.2: Key Performance Indicators
Quantitative Key Performance Indicators for Program 2.2
List cost-effective, innovative, clinically effective medicines on the PBS
Quantitative
Indicators
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
Number of prescriptions
subsidised through the PBS4
199m
212m
219m
227m
235m
$14.1m
$14.1m
$14.1m
$14.1m
$14.1m
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
$121.0m
$296.0m
$578.0m
$855.0m
$1,117.0m
Revenue received from the
cost recovery of the PBS
listing process
Increase the sustainability of the PBS
Quantitative
Indicator
Estimated savings to
Government from the price
disclosure program per
annum
4
This is a demand driven program. Targets have been revised to reflect current medicine usage.
82
Section 2 – Department Outcomes – 2 Access to Pharmaceutical Services
Program 2.3: Targeted assistance – pharmaceuticals
Program Objectives
The Australian Government will continue to provide fully subsidised access for
eligible patients to expensive and life-saving drugs for rare and life threatening
medical conditions through the Life Saving Drugs Program.
Ten drugs are currently funded through the program to treat seven serious and
very rare medical conditions. These conditions are: Fabry, Gaucher,
Mucopolysaccharidosis Types I, II and VI, Infantile Pompe disease and Paroxysmal
Nocturnal Haemoglobinuria. Each condition has separate treatment guidelines,
developed and administered using the advice of an expert disease advisory
committee.
In 2013-14, the Department will continue to facilitate and monitor access for new
and continuing patients to these medicines.
Program 2.3: Expenses
Table 2.4: Program Expenses
2012-13
Estimated
actual
$'000
2013-14
Budget
$'000
2014-15
Forward
year 1
$'000
2015-16
Forward
year 2
$'000
2016-17
Forward
year 3
$'000
Annual administered expenses
Ordinary annual services
Program support
151,016
3,368
153,336
3,148
158,692
3,127
160,277
3,146
161,887
3,198
Total Program 2.3 expenses
154,384
156,484
161,819
163,423
165,085
Program 2.3: Deliverables
Qualitative Deliverable for Program 2.3
Improve access to new and existing medicines for patients with life threatening
conditions
Qualitative Deliverable
2013-14 Reference Point or Target
Review program guidelines to ensure they
remain current and relevant
Program guidelines reviewed within agreed
timeframes
83
Outcome I 02
Improve access to new and existing medicines for patients with life threatening conditions
Budget Statements – Department of Health and Ageing
Quantitative Deliverable for Program 2.3
Improve access to new and existing medicines for patients with life threatening
conditions
Quantitative Deliverable
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
Number of patients assisted
through the Life Saving
Drugs Program
230
245
260
275
290
Program 2.3: Key Performance Indicators
Qualitative Key Performance Indicator for Program 2.3
Improve access to new and existing medicines for patients with life threatening
conditions
Qualitative Indicator
2013-14 Reference Point or Target
Eligible patients have timely access to the
Life Saving Drugs Program
Patient applications are processed within
30 calendar days of receipt
Quantitative Key Performance Indicator for Program 2.3
Improve access to new and existing medicines for patients with life threatening
conditions
Quantitative
Indicator
Percentage of eligible
patients with access to fully
subsidised medicines
through the Life Saving
Drugs Program
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
100%
100%
100%
100%
100%
Program 2.4: Targeted assistance – aids and appliances
Program Objectives
Provide support for people with diabetes
The Australian Government, through the National Diabetes Services Scheme
(NDSS), aims to ensure that people with diabetes have timely, reliable and
affordable access to products and services that help them effectively self-manage
their condition. The NDSS is administered by Diabetes Australia through a
funding agreement. In 2013-14, the Department, in conjunction with Diabetes
Australia, will continue to analyse and implement the outcomes of an integrated
review undertaken in 2012-13. The integrated review draws together a number of
independent reviews commissioned by Diabetes Australia to determine the future
84
Section 2 – Department Outcomes – 2 Access to Pharmaceutical Services
The Government also provides support to the families of children with type 1
diabetes through the Type 1 Diabetes Insulin Pump Program. This program
subsidises the cost of insulin pump therapy for those families with children under
the age of 18 who have type 1 diabetes and who meet the income limits.
Assist people with a stoma by providing stoma related products
The Australian Government assists eligible people with stomas 5 by providing them
with stoma related appliances (such as pouches, products to assist irrigation,
protective films and seals) through the Stoma Appliance Scheme.
An ongoing review of the clinical and cost effectiveness of all products listed on
the scheme will continue in 2013-14, and the outcomes will be implemented. The
outcomes of this review will help ensure that participants of this scheme continue
to have access to the most clinically suitable appliances to effectively manage their
condition and will also assist in improving the sustainability of the scheme.
Improve the quality of life for people with Epidermolysis Bullosa
The Australian Government aims to improve the quality of life for people with
Epidermolysis Bullosa6 through the National Epidermolysis Bullosa Dressing
Scheme. The scheme subsidises clinically appropriate and necessary dressings. The
Department works with clinical experts to ensure dressing treatment methods are
consistent with best-practice.
Program 2.4 is linked as follows:

The Department of Human Services (Services to the Community –
Program 1.1) to administer payment of claims from Stoma Associations for
stoma related appliances.
Program 2.4: Expenses
Table 2.5: Program Expenses
2012-13
Estimated
actual
$'000
2013-14
Budget
$'000
2014-15
Forward
year 1
$'000
2015-16
Forward
year 2
$'000
2016-17
Forward
year 3
$'000
Annual administered expenses
Ordinary annual services
Special appropriations
National Health Act 1953 aids and appliances
Program support
745
681
596
596
596
284,592
3,368
304,915
3,148
326,649
3,126
350,204
3,145
353,111
3,197
Total Program 2.4 expenses
288,705
308,744
330,371
353,945
356,904
5
An opening in the abdomen for evacuation of products from the bowel or bladder.
6
A genetic disease characterised by extremely fragile and blister prone skin.
85
Outcome I 02
arrangements for product supply and delivery, the product schedule and
registrant support services.
Budget Statements – Department of Health and Ageing
Program 2.4: Deliverables
Qualitative Deliverable for Program 2.4
Provide support for people with diabetes
Qualitative Deliverable
2013-14 Reference Point or Target
Provide access to insulin pumps and
associated consumables for children under
18 years of age with type 1 diabetes
Work with the scheme administrator to
ensure efficient insulin pump subsidies are
provided
Quantitative Deliverables for Program 2.4
Provide support for people with diabetes
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
Number of people with
diabetes receiving benefit
from the NDSS
1,180,000
1,280,000
1,400,000
1,526,000
1,656,000
Number of people under
18 years of age with type 1
diabetes receiving a
subsidised insulin pump
62
68
68
68
68
Quantitative Deliverables
Assist people with a stoma by providing stoma related products
Quantitative Deliverable
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
Number of people receiving
stoma related products
41,000
41,750
42,5007
43,250
44,000
Improve the quality of life for people with Epidermolysis Bullosa
Quantitative Deliverable
Number of people with
Epidermolysis Bullosa
receiving subsidised
dressings
7
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
79
83
87
91
95
Figures for 2014-15 and subsequent years have been reduced following identification of an error in estimates.
86
Section 2 – Department Outcomes – 2 Access to Pharmaceutical Services
Program 2.4: Key Performance Indicators
Quantitative Key Performance Indicators for Program 2.4
Quantitative
Indicator
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
Percentage of eligible people
with diabetes who are able
to access clinically
appropriate products
100%
100%
100%
100%
100%
Assist people with a stoma by providing stoma related products
Quantitative
Indicator
2012-13
Revised
Budget
2013-14
Budget
Target
2014-15
Forward
Year 1
2015-16
Forward
Year 2
2016-17
Forward
Year 3
Percentage of eligible people
with stomas who are able to
access clinically appropriate
products
100%
100%
100%
100%
100%
87
Outcome I 02
Provide support for people with diabetes
Budget Statements – Department of Health and Ageing
88